All Posts

Overview: • Under the radar companies • Huge upside • Difficult FDA approval behind them ⇒ Typical for drug device combo ⇒ 2 CRLs • But...

PRTA tech validated by big BMS collaboration • BMS is part owner of PRTA BMS & PRTA collaboration highlights: 3/20/18 CELG & PRTA enter...

Conclusion: Mixed positive Positives: Efficacy ACU193 appears to reduce plaque @ highest dose levels AFAIK 1st time plaque reduction shown by binding oligomers ABOS concludes plaque reduction similar to “approved BA Abs” Plaque clearance data only out to ~3 months so hard to know Donanemab is probably best at clearing plaque ( See comparative table ) Serum pK looks good for monthly dosing Assay Csf target engagement assay Looks like it works well enough to help clin dev Impre

But, which is the best?

Overview: • One of my favorite under the radar companies • Huge upside • Difficult FDA approval behind them   ⇒ Typical for drug device combo   ⇒ 2 CRLs • But still high risk/high reward stock Details: Single drug company • Furoscix   ⇒ SubQ furosemide via on body infusor   ⇒ Diuretic for fluid build up in chronic heart failure • Early commercial - Launched Feb ‘23 • Market opp $7B Sales Pitch: Large cost savings for Medicare & insurers ✔️Patients stay home instead of IV @ ho

But, which is the best? • Some anti-beta amyloids (ABs) made it ⇒ thru pos Ph3 ⇒ 1 full FDA approval But lots of ABs have died in...

Intro:

Summary: The Alzheimer's Association International Conference is taking place from July 16 - 20, 2023 Abstracts are embargoed until the...

Is $GRTX a buy into PDUFA - Aug 9, 2023?

ALHEIMER’S BREAKTHROUGH